Induction of robust type-1 CD8(+) T-cell responses in WHO grade II low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC

PURPOSE: WHO grade II low-grade gliomas (LGGs) with high risk factors for recurrence are mostly lethal despite current treatments. We conducted a phase I study to evaluate the safety and immunogenicity of subcutaneous vaccinations with synthetic peptides for glioma-associated antigen (GAA) epitopes...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Okada, Hideho, Butterfield, Lisa H., Hamilton, Ronald L., Hoji, Aki, Sakaki, Masashi, Ahn, Brian J., Kohanbash, Gary, Drappatz, Jan, Engh, Johnathan, Amankulor, Nduka, Lively, Mark O., Chan, Michael D., Salazar, Andres M., Shaw, Edward G., Potter, Douglas M., Lieberman, Frank S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297523/
https://ncbi.nlm.nih.gov/pubmed/25424847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1790
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia